1-855-378-42281-855-378-4228
One of the outpatient rehabilitation alternatives for individuals in Haviland struggling with opioid dependence and addiction is opioid maintenance therapy. Licensed clinics and doctors are certified to administer specific medications to opioid addicted clients, many that are opioids also and are addictive. With low enough amounts however, the user doesn't experience high feelings and also doesn't have severe cravings and is not experiencing opioid withdrawal. Methadone is the first drug administered for this sole purpose, but there are alternative choices to pick from.
Methadone is an opiate and can be taken at an outpatient clinic certified to dispense the drug, which is taken on a daily basis as a pill or liquid. The price of the drug is approximately $150 a month. Buprenorphine is also an opiate based drug, and is in pill form often taken one day on, one day off. But unlike Methadone that can only be administered in highly structured clinics, Buprenorphine can be and is prescribed and administered in doctor's offices. The monthly cost of buprenorphine is approximately three hundred dollars a month for the generic of the drug. There is also a version of buprenorphine that contains naloxone, that is a drug that blocks the effects of opioids. An individual consuming this version of the drug, also known as Suboxone, would find it more difficult to get high from opioids if they relapsed while taking the drug. It too is taken on a daily basis, and is priced approximately $450 a month. Naltrexone is an additional med taken in opioid maintenance therapy, but unlike the other drugs mentioned it is an opiate blocker and isn't an opiate. There is an option to take this drug as a monthly shot, which is called Vivitrol. As an opioid blocker, the drug prevents a person from experience high feelings from opioids, and in turn lowers the risk associated with relapse. This daily injection costs in the range of $1000 to $1200 monthly.
For All Alcohol and Drug Rehab Facilities In Haviland, Click Here.
